Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

R X Lan, Q Liu, P S Fan, S Y Lin, S R Fernando, D McCallion, R Pertwee, A Makriyannis

Research output: Contribution to journalArticle

383 Citations (Scopus)

Abstract

As a potent, specific antagonist for the brain cannabinoid receptor (CB1), the biarylpyrazole N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1) was the lead compound for initiating studies designed to examine the structure-activity relationships of related compounds and to search for more selective and potent cannabimimetic ligands. A series of pyrazole derivatives was designed and synthesized to aid in the characterization of the cannabinoid receptor binding sites and also to serve as potentially useful pharmacological probes. Therapeutically, such compounds may have the ability to antagonize harmful side effects of cannabinoids and cannabimimetic agents. Structural requirements for potent and selective brain cannabinoid CB1 receptor antagonistic activity included (a) a para-substituted phenyl ring at the 5-position, (b) a carboxamido group at the 3-position, and (c) a 2,4-dichlorophenyl substituent at the 1-position of the pyrazole ring. The most potent compound of this series contained a p-iodophenyl group at the 5-position, a piperidinyl carboxamide at the S-position, and a 2,4-dichlorophenyl group at the 1-position of the pyrazole ring. The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.

Original languageEnglish
Pages (from-to)769-776
Number of pages8
JournalJournal of Medicinal Chemistry
Volume42
Publication statusPublished - 1999

Keywords

  • PHARMACOLOGICAL CHARACTERIZATION
  • CB1 RECEPTOR
  • SR 141716A
  • BRAIN
  • INHIBITION
  • SR141716A
  • AGONISTS
  • BINDING
  • POTENT

Cite this

Lan, R. X., Liu, Q., Fan, P. S., Lin, S. Y., Fernando, S. R., McCallion, D., ... Makriyannis, A. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. Journal of Medicinal Chemistry, 42, 769-776.

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. / Lan, R X ; Liu, Q ; Fan, P S ; Lin, S Y ; Fernando, S R ; McCallion, D ; Pertwee, R ; Makriyannis, A .

In: Journal of Medicinal Chemistry, Vol. 42, 1999, p. 769-776.

Research output: Contribution to journalArticle

Lan, RX, Liu, Q, Fan, PS, Lin, SY, Fernando, SR, McCallion, D, Pertwee, R & Makriyannis, A 1999, 'Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists', Journal of Medicinal Chemistry, vol. 42, pp. 769-776.
Lan RX, Liu Q, Fan PS, Lin SY, Fernando SR, McCallion D et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. Journal of Medicinal Chemistry. 1999;42:769-776.
Lan, R X ; Liu, Q ; Fan, P S ; Lin, S Y ; Fernando, S R ; McCallion, D ; Pertwee, R ; Makriyannis, A . / Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. In: Journal of Medicinal Chemistry. 1999 ; Vol. 42. pp. 769-776.
@article{5fdfcee394c4453d934374b7abed74b3,
title = "Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists",
abstract = "As a potent, specific antagonist for the brain cannabinoid receptor (CB1), the biarylpyrazole N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1) was the lead compound for initiating studies designed to examine the structure-activity relationships of related compounds and to search for more selective and potent cannabimimetic ligands. A series of pyrazole derivatives was designed and synthesized to aid in the characterization of the cannabinoid receptor binding sites and also to serve as potentially useful pharmacological probes. Therapeutically, such compounds may have the ability to antagonize harmful side effects of cannabinoids and cannabimimetic agents. Structural requirements for potent and selective brain cannabinoid CB1 receptor antagonistic activity included (a) a para-substituted phenyl ring at the 5-position, (b) a carboxamido group at the 3-position, and (c) a 2,4-dichlorophenyl substituent at the 1-position of the pyrazole ring. The most potent compound of this series contained a p-iodophenyl group at the 5-position, a piperidinyl carboxamide at the S-position, and a 2,4-dichlorophenyl group at the 1-position of the pyrazole ring. The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.",
keywords = "PHARMACOLOGICAL CHARACTERIZATION, CB1 RECEPTOR, SR 141716A, BRAIN, INHIBITION, SR141716A, AGONISTS, BINDING, POTENT",
author = "Lan, {R X} and Q Liu and Fan, {P S} and Lin, {S Y} and Fernando, {S R} and D McCallion and R Pertwee and A Makriyannis",
year = "1999",
language = "English",
volume = "42",
pages = "769--776",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "AMER CHEMICAL SOC",

}

TY - JOUR

T1 - Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

AU - Lan, R X

AU - Liu, Q

AU - Fan, P S

AU - Lin, S Y

AU - Fernando, S R

AU - McCallion, D

AU - Pertwee, R

AU - Makriyannis, A

PY - 1999

Y1 - 1999

N2 - As a potent, specific antagonist for the brain cannabinoid receptor (CB1), the biarylpyrazole N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1) was the lead compound for initiating studies designed to examine the structure-activity relationships of related compounds and to search for more selective and potent cannabimimetic ligands. A series of pyrazole derivatives was designed and synthesized to aid in the characterization of the cannabinoid receptor binding sites and also to serve as potentially useful pharmacological probes. Therapeutically, such compounds may have the ability to antagonize harmful side effects of cannabinoids and cannabimimetic agents. Structural requirements for potent and selective brain cannabinoid CB1 receptor antagonistic activity included (a) a para-substituted phenyl ring at the 5-position, (b) a carboxamido group at the 3-position, and (c) a 2,4-dichlorophenyl substituent at the 1-position of the pyrazole ring. The most potent compound of this series contained a p-iodophenyl group at the 5-position, a piperidinyl carboxamide at the S-position, and a 2,4-dichlorophenyl group at the 1-position of the pyrazole ring. The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.

AB - As a potent, specific antagonist for the brain cannabinoid receptor (CB1), the biarylpyrazole N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A; 1) was the lead compound for initiating studies designed to examine the structure-activity relationships of related compounds and to search for more selective and potent cannabimimetic ligands. A series of pyrazole derivatives was designed and synthesized to aid in the characterization of the cannabinoid receptor binding sites and also to serve as potentially useful pharmacological probes. Therapeutically, such compounds may have the ability to antagonize harmful side effects of cannabinoids and cannabimimetic agents. Structural requirements for potent and selective brain cannabinoid CB1 receptor antagonistic activity included (a) a para-substituted phenyl ring at the 5-position, (b) a carboxamido group at the 3-position, and (c) a 2,4-dichlorophenyl substituent at the 1-position of the pyrazole ring. The most potent compound of this series contained a p-iodophenyl group at the 5-position, a piperidinyl carboxamide at the S-position, and a 2,4-dichlorophenyl group at the 1-position of the pyrazole ring. The iodinated nature of this compound offers additional utility as a gamma-enriching SPECT (single photon emission computed tomography) ligand that may be useful in characterizing brain CB1 receptor binding in vivo.

KW - PHARMACOLOGICAL CHARACTERIZATION

KW - CB1 RECEPTOR

KW - SR 141716A

KW - BRAIN

KW - INHIBITION

KW - SR141716A

KW - AGONISTS

KW - BINDING

KW - POTENT

M3 - Article

VL - 42

SP - 769

EP - 776

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

ER -